In a filing, BridgeBio Pharma Inc revealed its 10% Owner VIKING GLOBAL INVESTORS LP acquired Company’s shares for reported $106.99 million on Jan 31 ’25. In the deal valued at $34.90 per share,3,065,616 shares were bought.
Then, VIKING GLOBAL INVESTORS LP sold 3,065,616 shares, generating $106,989,998 in total proceeds. Upon selling the shares at $34.90, the 10% Owner now owns 22,055,375 shares.
Before that, STEPHENSON BRIAN C sold 68,000 shares. BridgeBio Pharma Inc shares valued at $2,467,761 were divested by the Secretary, Treasurer & CFO at a price of $36.29 per share. As a result of the transaction, STEPHENSON BRIAN C now holds 93,758 shares, worth roughly $2.98 million.
Scotiabank initiated its BridgeBio Pharma Inc [BBIO] rating to a Sector outperform in a research note published recently. A number of analysts have revised their coverage, including Oppenheimer’s analysts, who began to cover the stock in early October with a ‘”a Perform”‘ rating. Piper Sandler began covering BBIO with “an Overweight” recommendation on September 04, 2024.
Price Performance Review of BBIO
On Monday, BridgeBio Pharma Inc [NASDAQ:BBIO] saw its stock fall -0.28% to $31.76. Over the last five days, the stock has gained 2.35%. BridgeBio Pharma Inc shares have risen nearly 15.74% since the year began. Nevertheless, the stocks have fallen -5.95% over the past one year. While a 52-week high of $41.04 was reached on 01/27/25, a 52-week low of $21.62 was recorded on 01/02/25. SMA at 50 days reached $30.51, while 200 days put it at $27.31.
Levels Of Support And Resistance For BBIO Stock
The 24-hour chart illustrates a support level at 31.30, which if violated will result in even more drops to 30.83. On the upside, there is a resistance level at 32.61. A further resistance level may holdings at 33.45. The Relative Strength Index (RSI) on the 14-day chart is 46.34, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -2.47, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 86.70%. Stochastics %K at 18.27% indicates the stock is a buying.
How much short interest is there in BridgeBio Pharma Inc?
A steep rise in short interest was recorded in BridgeBio Pharma Inc stocks on 2025-01-15, growing by 3.26 million shares to a total of 20.38 million shares. Yahoo Finance data shows the prior-month short interest on 2024-12-13 was 17.12 million shares. There was a rise of 15.99%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on January 31, 2024 when BMO Capital Markets began covering the stock and recommended ‘”a Market perform”‘ rating along with a $37 price target.
